Back

Treating HFpEF: State of the art 2022

29 August 2022 (14:00 - 14:18)
Organised by:
Congress Presentation Part of: How to treat HFpEF in 2022 and beyond Chronic Heart Failure ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Scott Solomon

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

3 More presentations in this session

Presentation thumbnail
Efficacy of empagliflozin in patients with heart failure according to baseline KDIGO risk categories - findings from the EMPEROR-Pooled
Professor J. Butler (Dallas, US)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of sacubitril/valsartan according to frailty in heart failure with preserved ejection fraction: a post hoc analysis of the PARAGON-HF trial
Doctor J. Butt (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Digoxin improves systolic cardiac function in patients with AF and HFpEF: the RATE-AF randomised trial
Doctor K. Bunting (Birmingham, GB)
Abstract Slides Video

Access the full session

Session thumbnail
How to treat HFpEF in 2022 and beyond
Video

The Event

Event poster

ESC Congress 2022

29 August 2022 14:00 CET
You may be interested in
thumbnail
Congress Session
State-of-the art treatment of HFmrEF and HFpEF in 2023
thumbnail
Congress Presentation
How should we treat HFpEF?
thumbnail
Congress Session
Insights from recent HFpEF trials 1

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources